PLEASANTON, Calif.,
Oct. 11, 2012 /PRNewswire/
-- Thoratec Corporation (NASDAQ: THOR), a world leader in
device-based mechanical circulatory support (MCS) therapies to
save, support and restore failing hearts, today announced that its
Board of Directors has appointed Taylor C.
Harris to the position of Vice President and Chief Financial
Officer.
Mr. Harris joined Thoratec in 2010 as Senior Director of
Investor Relations and Business Development. Prior to joining
Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a
decade in several capacities, including as a Vice President in the
firm's Healthcare Investment Banking and Equity Research
departments. In these roles, Mr. Harris covered the medical device
sector as an investment research analyst and advised healthcare
companies on a broad range of strategic and capital markets
transactions. Mr. Harris holds a B.A. in Physics and
Economics from the University of North
Carolina at Chapel Hill.
"Over the past few years, Taylor has effectively driven a broad
range of initiatives at Thoratec, demonstrating strong leadership,
business knowledge and strategic vision," commented Gary Burbach, President and Chief Executive
Officer. "We are confident that Taylor will make increasingly
valuable contributions to Thoratec in the CFO role, as we continue
to grow our markets and expand our global business."
Mr. Burbach also expressed the Company's gratitude to
Roxanne Oulman, the company's Vice
President of Finance, who has been serving as interim Chief
Financial Officer since June 2011. "We appreciate Roxanne
shepherding the Company's financial functions through this
transition period," noted Burbach. "Thanks to her leadership, we
have been able to maintain absolute confidence in our financial and
accounting operations while we engaged in a robust process to
recruit a CFO."
About Thoratec
Thoratec is the world leader in mechanical circulatory
support with the broadest product portfolio to treat the full range
of clinical needs for patients suffering from advanced heart
failure. The company's products include the HeartMate LVAS and
Thoratec VAD, with more than 20,000 devices implanted in patients
suffering from heart failure. Thoratec also manufactures and
distributes the CentriMag and PediMag / PediVAS product lines.
Thoratec is headquartered in Pleasanton,
California. For more information, visit
www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation and IVAD, Thoratec
360, Shared Care and Thoratec Connect are trademarks of Thoratec
Corporation. CentriMag and PediMag are registered trademarks
of Thoratec LLC, and PediVAS is a registered trademark of Thoratec
Switzerland GmbH.
Many of the preceding paragraphs, particularly but not
exclusively those addressing guidance for fiscal 2012 financial
results or future performance contain forward-looking statements
within the meaning of Sections 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. These
statements can be identified by the words, "believes," "views,"
"expects," "plans," "projects," "hopes," "could," "will," and other
similar words. Actual results, events or performance could differ
materially from these forward-looking statements based on a variety
of factors, many of which are beyond Thoratec's control. Therefore,
readers are cautioned not to put undue reliance on these
statements. Investors are cautioned that all such statements
involve risks and uncertainties, including risks related to the
development of new products and new markets including Destination
Therapy, the growth of existing markets for our products, customer
and physician acceptance of Thoratec products, the ability to
improve financial performance, the effects of healthcare
reimbursement and coverage policies, the effects of competition and
the effects of any merger, acquisition and divestiture related
activities. Forward-looking statements contained in this press
release should be considered in light these factors and those
factors discussed from time to time in Thoratec's public reports
filed with the Securities and Exchange Commission, such as those
discussed under the heading, "Risk Factors," in Thoratec's most
recent annual report on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K and other SEC filings. These
forward-looking statements speak only as of the date hereof.
Thoratec undertakes no obligation to publicly release the results
of any revisions to these forward-looking statements that may be
made to reflect events or circumstances after the date hereof, or
to reflect the occurrence of unanticipated events.
SOURCE Thoratec Corporation